Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OT202 in Moderate to Severe Dry Eye
NCT06435182Phase 2Completed
- Sponsor
- Ocumension Biotech
- Start
- Apr 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of OT-202 in dry eye syndrome (DED), sponsored by Ocumension Biotech. Started Apr 2023; status: completed.
02
Drugs
OT-202
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT06435182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435182.